Midolat

General characteristics. Structure:

Active ingredient - a meldoniya a dihydrate of 250,00 mg.

Excipients - potato starch; silicon dioxide colloid; calcium stearate.

Structure of the capsule: titanium E 171 dioxide, gelatin.

Pharmacological properties:

The means improving metabolism, a gamma butyrobetaine analog. Suppresses gamma бутиробетаингидроксиназу, synthesis of a carnitine and transport of long-chain fatty acids through covers of cells oppresses, interferes with accumulation in cells of the activated forms of unoxidized fatty acids - a derivative acylcarnitine and acylcoenzyme A.
In the conditions of ischemia recovers balance of processes of delivery of oxygen and its consumption in cells, prevents disturbance of transport of ATP; along with it activates glycolysis which proceeds without additional consumption of oxygen. As a result of decrease in concentration of a carnitine the gamma butyrobetaine having vazodilatiruyushchy properties is strenuously synthesized. The mechanism of action defines variety of its pharmacological effects: increase in working capacity, reduction of symptoms of a mental and physical overstrain, activation of fabric and humoral immunity, cardiotyre-tread action.
In case of acute ischemic injury of a myocardium slows down formation of a necrotic zone, shortens the rehabilitation period. At heart failure increases contractility of a myocardium, increases tolerance to an exercise stress, reduces the frequency of attacks of stenocardia. At acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemia center, promotes redistribution of blood in favor of the ischemic site. It is effective at vascular and dystrophic pathology of an eyeground. Has tonic effect on TsNS, eliminates functional disturbances from a nervous system at patients with an alcoholism at an abstinence syndrome.

Pharmacokinetics. After intake it is quickly soaked up from a GIT. Bioavailability makes about 78%. Cmax in plasma is reached in 1-2 h after reception. It Biotransformirutsya in an organism with formation of two main metabolites which are removed by kidneys. T1/2 makes 3-6 h and depends on a dose.

Indications to use:

For intake or in/in introductions: as a part of complex therapy of an ischemic heart disease (stenocardia, a myocardial infarction), chronic heart failure, a dishormonal cardiomyopathy; as a part of complex therapy of acute and chronic disorders of cerebral circulation (strokes and cerebrovascular insufficiency); the lowered working capacity, a physical overstrain (including at athletes), the postoperative period for rehabilitation acceleration; an abstinence syndrome at an alcoholism (in a combination with specific therapy of alcoholism).

For parabulbar introduction: an acute disorder of blood circulation in a retina, a hemophthalmia and retinal apoplexies of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (including diabetic and hypertensive) - only for parabulbar introduction.

Route of administration and doses:

Due to a possibility of development of exciting effect use in the first half of day is recommended. The dose is established individually in dependence on indications and a way of introduction.
At intake the single dose makes 0.25-1 g, frequency rate of reception and duration of treatment depend on indications.
At in introduction the dose makes 0.5-1 g of 1 times/, duration of treatment depends on indications.

Parabulbarno enter on 0.5 ml of solution for injections with concentration 500 mg / 5 ml within 10 days.

Features of use:

With care to apply at diseases of a liver and/or kidneys, especially for a long time.

Long-term experience of treatment of an acute myocardial infarction and unstable stenocardia in cardiological departments shows that meldoniya are not means of the first row at an acute coronary syndrome.

Side effects:

- From cardiovascular system: seldom - tachycardia, changes of the ABP.
- From TsNS: seldom - psychomotor excitement.
- From the alimentary system: seldom - dispeptic symptoms.
- Allergic reactions: seldom - a skin itch, reddenings, rash, hypostasis.

Interaction with other medicines:

At combined use of meldoniya strengthens action of anti-anginal means, some hypotensive drugs, cardiac glycosides.

At simultaneous use a meldoniya with nitroglycerine, nifedipine, alpha adrenoblockers, anti-hypertensive means and peripheral vazodilatator development of moderate tachycardia, arterial hypotension (at these combinations care is required) is possible.

Contraindications:

Increase in intracranial pressure (including at disturbance of venous outflow, intracranial tumors), pregnancy, the period of a lactation (breastfeeding), children's and teenage age up to 18 years, hypersensitivity to a meldoniya.

Use at pregnancy and feeding by a breast
At pregnancy and in the period of a lactation (breastfeeding) use of drug is contraindicated.

Use at abnormal liver functions
With care to apply at liver diseases, especially for a long time.

Use at renal failures
With care to apply at diseases of kidneys, especially for a long time.

Use for children
At children and teenagers aged up to 18 years efficiency and safety the meldoniya is not established.

Meldony in the form of capsules is contraindicated for use for children and teenagers aged up to 18 years; in the form of syrup - at children aged up to 12 years.

Overdose:

Cases of overdose are not established.

Storage conditions:

List B.
In the dry place at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Capsules of 250 mg.
On 10 capsules in a blister strip packaging. On 2; 4 blister strip packagings together with the application instruction place in a pack from a cardboard.